Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 5, 2016, Pages 936-944

  Ballestri, Stefano ^a   Zona, Stefano ^c   Targher, Giovanni ^d   Romagnoli, Dante ^b   Baldelli, Enrica ^b   Nascimbeni, Fabio ^b   Roverato, Alberto ^e   Guaraldi, Giovanni ^c   Lonardo, Amedeo ^b  

^a Pavullo Hospital   (Italy)

^b AUSL Modena   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ALT; AST; Diabetes; GGT; Liver enzymes; Metabolic Syndrome; NAFLD; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER; GAMMA-GLUTAMYLTRANSFERASE, HUMAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; ECHOGRAPHY; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); BLOOD; CHI SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; ENZYME ASSAY; INCIDENCE; META ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT; TIME FACTOR;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CLINICAL ENZYME TESTS; DIABETES MELLITUS, TYPE 2; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INCIDENCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; ULTRASONOGRAPHY;

EID: 84964510429     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13264     Document Type: Article

References (75)

1. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 2015; 47: 181-90.
2. Nascimbeni F, Pais R, Bellentani S et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013; 59: 859-71.
3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011; 43: 617-49.
4. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 2008; 61: 344-9.
5. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-58.
6. Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
7. Jiamjarasrangsi W, Sangwatanaroj W, Lohsoonthorn V, Lertmaharit S. Increased alanine aminotransferase level and future risk of type 2 diabetes and impaired fasting glucose among the employees in a university hospital in Thailand. Diabetes Metab. 2008; 34: 283-9.
8. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am. J. Gastroenterol. 2009; 104: 861-7.
9. Lee DH, Ha MH, Kim JH et al. Gammaglutamyltransferase and diabetes-a 4year follow-up study. Diabetologia 2003; 46: 359-64.
10. André P, Balkau B, Born C et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. Diabetes Metab. 2005; 31: 542-50.
11. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. Serum γ-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J. Intern. Med. 2005; 258: 527-35.
12. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-8.
13. Sato KK, Hayashi T, Nakamura Y et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 2008; 31: 1230-6.
14. Monami M, Bardini G, Lamanna C et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008; 57: 387-92.
15. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab. Res. Rev. 2009; 25: 64-9.
16. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-32.
17. Ahn HR, Shin MH, Nam HS et al. The association between liver enzymes and risk of type 2 diabetes: the Namwon study. Diabetol. Metab. Syndr. 2014; 6: 14.
18. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J. Epidemiol. 2003; 13: 15-21.
19. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 2007; 22: 1086-91.
20. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940-4.
21. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet. Med. 2008; 25: 476-81.
22. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57: 1378-83.
23. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population. Am. J. Gastroenterol. 2013; 108: 1861-8.
24. Kasturiratne A, Weerasinghe S, Dassanayake AS et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J. Gastroenterol. Hepatol. 2013; 28: 142-7.
25. Zelber-Sagi S, Lotan R, Shibolet O et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013; 33: 1406-12.
26. Ming J, Xu S, Gao B et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int. 2015; 35: 2401-7.
27. André P, Balkau B, Vol S, Charles MA, Eschwège E, DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007; 30: 2355-61.
28. Jo SK, Lee WY, Rhee EJ et al. Serum (gamma)-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin. Chim. Acta 2009; 403: 234-40.
29. Xu Y, Bi YF, Xu M et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase and γ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people. J. Diabetes 2011; 3: 38-47.
30. Suh BS. The association between serum gamma-glutamyltransferase within normal levels and metabolic syndrome in office workers: a 4-year follow-up study. Korean J. Fam. Med. 2012; 33: 51-8.
31. Ryoo JH, Choi JM, Moon SY et al. The clinical availability of nonalcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013; 227: 398-403.
32. Zhang T, Zhang Y, Zhang C et al. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One 2014; 9: e96651.
33. Vozarova B, Stefan N, Lindsay RS et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-95.
34. Sattar N, Scherbakova O, Ford I et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53: 2855-60.
35. Hanley AJ, WilliaMetS K, Festa A et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623-32.
36. Schindhelm RK, Dekker JM, Nijpels G, Heine RJ, Diamant M. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study. Diabetes Care 2005; 28: 2812.
37. Nannipieri M, Gonzales C, Baldi S et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28: 1757-62.
38. Cho NH, Jang HC, Choi SH et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care 2007; 30: 2566-8.
39. Doi Y, Kubo M, Yonemoto K et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity 2007; 15: 1841-50.
40. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-44.
41. Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008; 31: 1138-43.
42. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741-50.
43. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F, Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010; 10: 56.
44. Schneider AL, Lazo M, Ndumele CE et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabet. Med. 2013; 30: 926-33.
45. Lee DH, Jacobs DR Jr, Gross M et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin. Chem. 2003; 49: 1358-66.
46. Hanley AJ, WilliaMetS K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-7.
47. Lee DS, Evans JC, Robins SJ et al. Gamma glutamyltransferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 127-33.
48. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am. J. Gastroenterol. 2009; 104: 1715-22.
49. Ryu S, Chang Y, Woo HY et al. Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men. Metab. Clin. Exp. 2010; 59: 683-9.
50. Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Doğan Y. Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring) 2012; 20: 842-8.
51. Chun H, Park SK, Ryoo JH. Association of serum γ-glutamyltransferase level and incident prehypertension in Korean men. J. Korean Med. Sci. 2013; 28: 1603-8.
52. Suh YJ, Park SK, Choi JM, Ryoo JH. The clinical importance of serum γ-glutamyltransferase level as an early predictor of obesity development in Korean men. Atherosclerosis 2013; 227: 437-41.
53. Lee JH, Um MH, Park YK. The association of metabolic syndrome and serum γ-glutamyl transpeptidase: a 4-year cohort study of 3, 698 korean male workers. Clin. Nutr. Res. 2013; 2: 67-75.
54. Ryoo JH, Oh CM, Kim HS, Park SK, Choi JM. Clinical association between serum γ-glutamyltransferase levels and the development of insulin resistance in Korean men: a 5-year follow-up study. Diabet. Med. 2014; 31: 455-61.
55. Oka R, Aizawa T, Yagi K, Hayashi K, Kawashiri M, Yamagishi M. Elevated liver enzymes are related to progression to impaired glucose tolerance in Japanese men. Diabet. Med. 2014; 31: 552-8.
56. Cicero AF, D'Addato S, Reggi A, Marchesini G, Borghi C, Heart Study B. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab. Syndr. Relat. Disord. 2013; 11: 412-6.
57. Liu Z, Que S, Ning H, Wang L, Peng T. Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studies. PLoS One 2013; 8: e80596.
58. Kunutsor SK, Seddoh D. Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship. PLoS One 2014; 9 e96068.
59. Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int. J. Clin. Pract. 2012; 66: 692-8.
60. Kunutsor SK, Apekey TA, Seddoh D. Gamma-glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int. J. Clin. Pract. 2015; 69: 136-44.
61. Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev. Gastroenterol. Hepatol. 2015; 9: 603-27.
62. Bril F, Ortiz-Lopez C, Lomonaco R et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015; 35: 2139-46.
63. Arulanandan A, Ang B, Bettencourt R et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2015; 13: 1513-20.
64. Non-alcoholic fatty liver disease (NAFLD) study group, dedicated to the memory of Prof. Paola Loria; Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 2015 Aug 14. pii: S1590-8658(15)00568-X. doi:. DOI: 10.1016/j.dld.2015.08.004. [Epub ahead of print].
65. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
66. Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U. S. A. 2009; 106: 15430-5.
67. Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 2010; 18: 1510-5.
68. Kumashiro N, Erion DM, Zhang D et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 16381-5.
69. Cantley JL, Yoshimura T, Camporez JP et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 1869-74.
70. Chitraju C, Trötzmüller M, Hartler J et al. The impact of genetic stress by ATGL deficiency on the lipidome of lipid droplets from murine hepatocytes. J. Lipid Res. 2013; 54: 2185-94.
71. Byrne CD, Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015; 62 (1 Suppl): S47-64.
72. Meex RC, Hoy AJ, Morris A et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab. 2015. DOI: 10.1016/j.cmet.2015.09.023.
73. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care 2015; 38: 1673-9.
74. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J. Clin. Endocrinol. Metab. 2013; 98: 3637-43.
75. Orozco LJ, Buchleitner AM, Gimenez-Perez G et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2008 CD003054.